Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll

Sumitomo Pharma’s group sales in the first quarter of FY2023 tanked by over 50% year on year as the loss of exclusivity of its flagship antipsychotic agent Latuda (lurasidone) in the US wreaked havoc on its earnings. In April-June, the...read more